The Bethesda System For Reporting Thyroid Cytop... Access

The sample did not have enough cells to make a diagnosis. II: Benign: High probability of being non-cancerous.

Indeterminate; high risk of being a follicular tumor, often requiring surgery to differentiate.

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) arose from a need to standardize how doctors report thyroid biopsy results, moving away from vague, subjective language towards a uniform system that helps predict cancer risk. The Story of the Bethesda System The Bethesda System for Reporting Thyroid Cytop...

Before this system was finalized (originally around 2010 and updated in 2023), different laboratories used different terms to describe thyroid fine-needle aspiration (FNA) samples, causing confusion for clinicians. The Bethesda System was developed through an NIH-sponsored conference to create a common language.

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Bethesda System for Reporting Thyroid Cytopathology Defin The sample did not have enough cells to make a diagnosis

Each category helps clinicians understand the likelihood of malignancy to guide treatment (e.g., surveillance vs. surgery).

Indeterminate; the cells look unusual, but not definitely cancerous. This is for informational purposes only

It categorizes thyroid nodules into six distinct groups based on the fine needle aspiration cytology (FNAC) results, each associated with a specific risk of malignancy (RoM) and recommended management: